Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
Currency in USD
Disclaimer
1.400
+0.030
(+2.19%)
Closed
1.390
-0.010
(-0.71%)
Pre Market
Real-time Data
Day's Range
1.325
1.430
52 wk Range
0.640
2.040
Volume
1,597,219
Prev. Close
1.37
Open
1.35
Day's Range
1.325-1.43
52 wk Range
0.64-2.04
Volume
1,597,219
Average Volume (3m)
3,135,707
1-Year Change
-22.65%
Shares Outstanding
173,666,805
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
4.158
Upside +197.021%

People Also Watch

3.3500
IMPP
-1.18%
3.2300
POAI
-7.45%
3.340
ARDX
+3.41%
3.11
UCAR
-4.89%

Rigel Pharmaceuticals Inc News

Rigel Pharmaceuticals Inc Analysis

Rigel Pharmaceuticals Inc Company Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The Company's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).